AXSM241220P40000
- 0.00
- 0.000.00%
Axsome Therapeutics Newsroom
Cantor Fitzgerald Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $121
Ladenburg Thalmann Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $175
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $116 to $150
RBC Lifts Price Target on Axsome Therapeutics to $132 From $131, Keeps Outperform Rating
Axsome Therapeutics Is Maintained at Outperform by Baird
Axsome Therapeutics Price Target Maintained With a $130.00/Share by Needham
Axsome Therapeutics: Strong Performance, Promising Pipeline, and Buy Rating Affirmed by Joseph Thome
Axsome Therapeutics Analyst Ratings
Needham Reiterates Buy on Axsome Therapeutics, Maintains $130 Price Target
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $115
Strong Commercial Performance of Auvelity Drives Buy Rating for Axsome Therapeutics
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $115
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $115
Wells Fargo Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $140
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $115
Buy Rating Justified for Axsome Therapeutics Amidst Strong Auvelity Launch and Promising Sales Trajectory
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $106
Axsome Therapeutics Is Maintained at Outperform by RBC Capital
Axsome Therapeutics Analyst Ratings